Citizens National Bank Trust Department Has $1.41 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Citizens National Bank Trust Department boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,798 shares of the medical equipment provider’s stock after acquiring an additional 298 shares during the period. Citizens National Bank Trust Department’s holdings in Lantheus were worth $1,405,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Daiwa Securities Group Inc. purchased a new stake in shares of Lantheus in the first quarter valued at about $1,269,000. Nordea Investment Management AB raised its holdings in shares of Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after purchasing an additional 14,147 shares during the last quarter. Hancock Whitney Corp raised its holdings in shares of Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Lantheus in the second quarter valued at about $290,000. Finally, Pitcairn Co. raised its holdings in shares of Lantheus by 117.0% in the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 4,509 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH stock opened at $107.98 on Monday. The firm has a 50 day moving average of $108.13 and a 200-day moving average of $94.87. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm has a market capitalization of $7.50 billion, a P/E ratio of 17.70 and a beta of 0.51.

Insider Activity at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on LNTH shares. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Finally, JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.